title: [Clinical studies on locoregional immunochemotherapy of peritonitis carcinomatosa].
abstract: Although 58 patients with peritonitis carcinomatosa underwent multidisciplinary therapy over the last 5 years in our department, about half of them died within 3 months after treatment. In addition, the prognosis was poor for gastric and colon cancer patients, who had macroscopic peritoneal dissemination. Therefore intraoperative intraperitoneal administration of either BRM or anticancer drugs was performed for the microscopic peritoneal dissemination of the cancer, and the immunological response in the peritoneal cavity was examined. In terms of subpopulation of peritoneal exudate cells, neutrophil leucocytes were predominant and thereafter lymphocytes increased. As for the cytokines in the exudate from peritoneal cavity, the concentration of interleukin-6 peaked within 24 hours after administration, followed by a gradual decrease, while the concentration of interferon-gamma was detectable at more than 24 hours after operation, followed by a gradual increase. Tumor necrosis factor-alpha was also detectable in the exudate. Its concentration decreased when both OK-432 and MMC were administered, but it increased when CDDP was administered. The above results indicated that preventive intraoperative intraperitoneal administration of BRM and anticancer drugs should bring about individual immunokinetic modulation in tumor bearing host and both cytokines and immunocytes could play an important role in locoregional tumor immunity.
authors.affiliation: 2nd Dept. of Surgery, Gifu University School of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: S
authors.initials: S
authors.lastname: Saji
authors.forename: T
authors.initials: T
authors.lastname: Furuta
authors.forename: S
authors.initials: S
authors.lastname: Azuma
authors.forename: K
authors.initials: K
authors.lastname: Miya
authors.forename: T
authors.initials: T
authors.lastname: Umemoto
authors.forename: H
authors.initials: H
authors.lastname: Takao
authors.forename: M
authors.initials: M
authors.lastname: Kato
authors.forename: A
authors.initials: A
authors.lastname: Kanno
mesh_terms: D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D007263:Infusions, Parenteral; D016685:Mitomycin / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000276:immunology; D010538:Peritonitis / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000150:complications* / Q000276:immunology
chemical_list: D010844:Picibanil; D016685:Mitomycin; D002945:Cisplatin